Evidence-based treatment of systemic sclerosis;Evidenz-basierte therapie der systemischen sklerose

Zeitschrift fur Rheumatologie

Volumn 60, Issue 6, 2001, Pages 464-468

  Genth, E ^a  

^a Rheumaklinik und Rheumaforschungsinstitut Aachen   (Germany)

Author keywords

Evidence based medicine; Systemic sclerosis; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOMPERIDONE; GLUCOCORTICOID; LOSARTAN; METHOTREXATE; METOCLOPRAMIDE; NIFEDIPINE; OCTREOTIDE; PRAZOSIN; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE;

CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE MOTILITY; INTESTINE PSEUDOOBSTRUCTION; RAYNAUD PHENOMENON; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS; TREATMENT PLANNING;

ANTIRHEUMATIC AGENTS; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 0035696215     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003930170013     Document Type: Conference Paper

References (53)

1. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide
2. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
3. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon
4. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease
5. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma
6. Measuring disease activity and severity in scleroderma
7. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients
8. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea
9. Inefficacy of diltiazem in the treatment of Raynaud's phenomenon with associated connective tissue disease: A double blind placebo controlled study
10. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres
11. Global improvement of systemic scleroderma under long-term administration of octreotide
12. Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial
13. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis)
14. Rational therapy in the treatment of systemic sclerosis
15. Treatment of progressive systemic sclerosis by plasma exchange: Long-term results in 40 patients
16. Mortality and causes of death in a Swedish series of systemic sclerosis patients
17. Generalized scleroderma. Treatment with an immunosuppressive agent
18. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon
19. The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: A controlled manometric study
20. Clinical and prognostic associations based on serum anti nuclear antibodies in Japanese patients with systemic sclerosis
21. Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin
22. Drug treatment of scleroderma
23. Progressive systemic sclerosis - Long-term treatment with azathioprin
24. Involvement of the small intestine in systemic scleroderma
25. Progressive systemic sclerosis
26. D-penicillamine treatment of lung involvement in patients with systemic sclerosis (scleroderma)
27. Cyclosporin and tacrolimus: Their use in a routine clinical setting for scleroderma
28. Octreotide in gastrointestinal motility disorders
29. Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis
30. Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis
31. Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis
32. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis
33. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis
34. Helicobacter pylori in patients with systemic sclerosis: Detection with the 13C-urea breath test and eradication
35. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases
36. Parvovirus arthropathy outbreak in southwestern United States
37. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial
38. Low-dose methotrexate in the treatment of widespread morphea
39. Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study
40. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease
41. Gastrointestinal motility disorders in scleroderma
42. Gastrointestinal features of scleroderma
43. Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors
44. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study
45. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis
46. Long-term outcomes of scleroderma renal crisis
47. Rational use of calcium-channel antagonists in Raynaud's phenomenon
48. Use of anti-thymocyte globulin in the management of refractory systemic autoimmune diseases
49. Physiotherapie der kollagenosen mit besonderer berücksichtigung der sklerodermie
50. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial
51. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions
52. Nifedipine in primary Raynaud's phenomenon and in scleroderma: Oral versus sublingual hemodynamic effects